Biogen Inc. $BIIB Shares Acquired by TD Waterhouse Canada Inc.

TD Waterhouse Canada Inc. boosted its position in Biogen Inc. (NASDAQ:BIIB) by 313.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,855 shares of the biotechnology company’s stock after buying an additional 2,165 shares during the period. TD Waterhouse Canada Inc.’s holdings in Biogen were worth $645,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in Biogen in the second quarter valued at approximately $3,453,878,000. Primecap Management Co. CA bought a new stake in shares of Biogen during the second quarter valued at approximately $3,274,304,000. Wellington Management Group LLP raised its position in shares of Biogen by 5.3% during the second quarter. Wellington Management Group LLP now owns 3,117,469 shares of the biotechnology company’s stock worth $673,560,000 after purchasing an additional 155,828 shares during the period. Amundi raised its position in shares of Biogen by 91.8% during the second quarter. Amundi now owns 1,516,831 shares of the biotechnology company’s stock worth $327,727,000 after purchasing an additional 726,004 shares during the period. Finally, Legal & General Group Plc acquired a new position in shares of Biogen during the second quarter worth approximately $322,640,000. 87.93% of the stock is owned by institutional investors and hedge funds.

Biogen Stock Performance

Shares of BIIB stock opened at $253.84 on Friday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.26 and a current ratio of 1.87. The firm has a market cap of $37.50 billion, a price-to-earnings ratio of 44.93, a P/E/G ratio of 2.68 and a beta of 0.09. Biogen Inc. has a 52 week low of $138.00 and a 52 week high of $254.41. The firm’s 50-day simple moving average is $222.78 and its two-hundred day simple moving average is $205.73.

Biogen (NASDAQ:BIIB) last released its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, beating analysts’ consensus estimates of $2.94 by $0.66. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The firm had revenue of $2.74 billion during the quarter, compared to the consensus estimate of $2.46 billion. During the same period in the prior year, the firm earned $5.47 EPS. The company’s revenue was up 3.4% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. As a group, equities analysts forecast that Biogen Inc. will post 12.31 earnings per share for the current year.

Key Headlines Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Wells Fargo raised its price target on Biogen, adding to a series of upward analyst revisions and reinforcing optimism about the company’s outlook. Biogen Stock Gets Price Target Boost from Wells Fargo
• Positive Sentiment: Bank of America increased its Biogen price target to $244 from $219. Although the firm maintained a Neutral rating, the revision reflects improved expectations as analysts update their models ahead of earnings. Biogen on BofA Price Target Hike
• Positive Sentiment: Several previews suggest Biogen could exceed third-quarter earnings estimates, supported by favorable analyst expectations and the potential for continued progress across its late-stage drug pipeline. Biogen Expected to Beat Earnings Estimates
• Neutral Sentiment: Wedbush kept a Hold rating on Biogen, indicating that valuation and near-term catalysts may already be reflected in the share price. Wedbush Remains a Hold on Biogen
• Negative Sentiment: Bank of America’s $244 target remains below the stock’s recent trading level, implying limited upside or potential downside despite the target increase. Analysts also characterize the upcoming quarter as relatively quiet, and earnings previews warn that disappointment remains possible.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on BIIB. BMO Capital Markets reiterated a “market perform” rating and issued a $220.00 target price on shares of Biogen in a report on Monday, October 12th. TD Cowen boosted their price target on shares of Biogen from $225.00 to $250.00 and gave the company a “buy” rating in a research note on Wednesday. Wells Fargo & Company boosted their price target on shares of Biogen from $250.00 to $310.00 and gave the company an “overweight” rating in a research note on Tuesday. HC Wainwright upped their price objective on shares of Biogen from $237.00 to $251.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Finally, Bank of America raised their price objective on shares of Biogen from $219.00 to $244.00 and gave the company a “neutral” rating in a research note on Thursday. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $241.89.

About Biogen

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.